Mycolic acids, a promising mycobacterial ligand for targeting of nanoencapsulated drugs in tuberculosis

Journal of Controlled Release

Volumn 211, Issue , 2015, Pages 94-104

  Lemmer, Yolandy ^a   Kalombo, Lonji ^a   Pietersen, Ray Dean ^b   Jones, Arwyn T ^c   Semete Makokotlela, Boitumelo ^a   Van Wyngaardt, Sandra ^d   Ramalapa, Bathabile ^a   Stoltz, Anton C ^d   Baker, Bienyameen ^b   Verschoor, Jan A ^d   Swai, Hulda S ^a   De Chastellier, Chantal ^e  

^a DSI CSIR Nanotechnology Innovation Centre   (South Africa)

^b STELLENBOSCH UNIVERSITY   (South Africa)

^c CARDIFF UNIVERSITY   (United Kingdom)

^d UNIVERSITY OF PRETORIA   (South Africa)

^e CENTRE D IMMUNOLOGIE DE MARSEILLE LUMINY   (France)

Author keywords

Electron microscopy; Mycolic acids; Nanodrug delivery; Phagosomes; Targeting; Tuberculosis

Indexed keywords

COPOLYMERS; ELECTRON MICROSCOPES; ELECTRON MICROSCOPY; EMULSIFICATION; LIGANDS; NANOPARTICLES;

MYCOLIC ACIDS; NANODRUG DELIVERY; PHAGOSOMES; TARGETING; TUBERCULOSIS;

TUBES (COMPONENTS);

MYCOLIC ACID; NANOPARTICLE; POLYGLACTIN; TUBERCULOSTATIC AGENT; LIGAND;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL STRAIN; DRUG DELIVERY SYSTEM; DRUG DESIGN; ELECTRON MICROSCOPY; EMULSION; MACROPHAGE; MOUSE; MYCOBACTERIUM AVIUM; MYCOBACTERIUM BOVIS BCG; NANOENCAPSULATION; NANOTECHNOLOGY; NONHUMAN; PHAGOLYSOSOME; PHAGOSOME; PRIORITY JOURNAL; TUBERCULOSIS; ANIMAL; C57BL MOUSE; DRUG EFFECTS; FEMALE; HUMAN; METABOLISM; MYCOBACTERIUM BOVIS; MYCOBACTERIUM TUBERCULOSIS; PROCEDURES;

ANIMALS; ANTITUBERCULAR AGENTS; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; LIGANDS; MICE; MICE, INBRED C57BL; MYCOBACTERIUM BOVIS; MYCOBACTERIUM TUBERCULOSIS; MYCOLIC ACIDS; NANOPARTICLES; TUBERCULOSIS;

EID: 84934978844     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2015.06.005     Document Type: Article

References (72)

1. WHO Global Tuberculosis Report WHO/HTM/TB/2013.11 2013
2. F.A. Drobniewski, A.L. Pozniak, and A.H. Uttley Tuberculosis and AIDS J. Med. Microbiol. 43 1995 85 91
3. H. McIlleron, G. Meintjes, W.J. Burman, and G. Maartens Complications of antiretroviral therapy in patients with tuberculosis: drug interactions, toxicity, and immune reconstitution inflammatory syndrome J. Infect. Dis. 196 2007 S63 S75
4. A. Sosnik, A.M. Carcaboso, R.J. Glisoni, M.A. Moretton, and D.A. Chiappetta New old challenges in tuberculosis: potentially effective nanotechnologies in drug delivery Adv. Drug Deliv. Rev. 62 2009 547 559
5. WHO Guidelines for the Programmatic Management of Drug-Resistant TB WHO/HTM/TB/2011.16 2011
6. E. Dubnau, J. Chan, C. Raynaud, V.P. Mohan, M.A. Laneelle, K. Yu, A. Quemard, I. Smith, and M. Daffe Oxygenated mycolic acids are necessary for virulence of Mycobacterium tuberculosis in mice Mol. Microbiol. 36 2000 630 637
7. A. Kumari, S.K. Yadav, and S.C. Yadav Biodegradable polymeric nanoparticles based drug delivery systems Colloids Surf. B 75 2010 1 18
8. K.S. Soppimath, T.M. Aminabhavi, A.R. Kulkarni, and W.E. Rudzinski Biodegradable polymeric nanoparticles as drug delivery devices J. Control. Release 70 2001 1 20
9. P. Thapa, G. Zhang, C. Xia, A. Gelbard, W.W. Overwijk, C. Liu, P. Hwu, D.Z. Chang, A. Courtney, J.K. Sastry, P.G. Wang, C. Li, and D. Zhou Nanoparticle formulated alpha-galactosylceramide activates NKT cells without inducing anergy Vaccine 27 2009 3484 3488
10. K.O. Kisich, S. Gelperina, M.P. Higgins, S. Wilson, E. Shipulo, E. Oganesyan, and L. Heifets Encapsulation of moxifloxacin within poly(butyl cyanoacrylate) nanoparticles enhances efficacy against intracellular Mycobacterium tuberculosis Int. J. Pharm. 345 2007 154 162
11. B. Semete, L. Booysen, Y. Lemmer, L. Kalombo, L. Katata, J. Verschoor, and H.S. Swai In vivo evaluation of the biodistribution and safety of PLGA nanoparticles as drug delivery systems Nanomedicine 6 2010 662 671
12. J. Panyam, and V. Labhasetwar Biodegradable nanoparticles for drug and gene delivery to cells and tissue Adv. Drug Deliv. Rev. 55 2003 329 347
13. D. Dube, G.P. Agrawal, and S.P. Vyas Tuberculosis: from molecular pathogenesis to effective drug carrier design Drug Discov. Today 17 2012 760 773
14. D.E. Minnikin Lipids: Complex Lipids, their Chemistry, Biosynthesis and Role 1982 Academic Press London, UK
15. G. Dobson, D.E. Minnikin, S.M. Minnikin, J.H. Parlett, M. Goodfellow, M. Ridell, and M. Magnusson Systematic analysis of complex mycobacterial lipids Chemical Methods of Bacterial Systematics 1985 Academic Press London
16. Y. Fujita, Y. Okamotoa, Y. Uenishib, M. Sunagawab, T. Uchiyamac, and I. Yano Molecular and supra-molecular structure related differences in toxicity and granulomatogenic activity of mycobacterial cord factor in mice Microb. Pathog. 43 2007 10 21
17. J. Korf, A. Stoltz, J. Verschoor, P. De Baetselier, and J. Grooten The Mycobacterium tuberculosis cell wall component mycolic acid elicits pathogen-associated host innate immune responses Eur. J. Immunol. 35 2005 890 900
18. J.E. Korf, G. Pynaert, K. Tournoy, T. Boonefaes, A. van Oosterhout, D. Ginneberge, A. Haegeman, J.A. Verschoor, P. De Baetseller, and J. Grooten Macrophage reprogramming by mycolic acids promotes a tolerogenic response in experimental asthma Am. J. Respir. Crit. Care Med. 174 2006 152 160
19. P. Peyron, J. Vaubourgeix, Y. Poquet, F. Levillain, C. Botanch, F. Bardou, M. Daffe', J. Emile, B. Marchou, P. Cardona, C. de Chastellier, and F. Altare Foamy macrophages from tuberculous patients granulomas constitute a nutrient-rich reservoir for M. tuberculosis persistence PLoS Pathog. 4 2008 e1000204
20. J.A. Verschoor, M.S. Baird, and J. Grooten Towards understanding the functional diversity of cell wall mycolic acids of Mycobacterium tuberculosis Prog. Lipid Res. 51 2012 325 339
21. Y. Benadie, M. Deysel, D.G. Siko, V.V. Roberts, S. Van Wyngaardt, S.T. Thanyani, G. Sekanka, A.M. Ten Bokum, L.A. Collett, J. Grooten, M.S. Baird, and J.A. Verschoor Cholesteroid nature of free mycolic acids from M. tuberculosis Chem. Phys. Lipids 152 2008 95 103
22. E.V. Beckman, S.A. Porcelli, C.T. Morita, S.M. Behar, S.T. Furlong, and M.B. Brenner Recognition of a lipid antigen by CD1-restricted αβ+ T cells Nature 372 1994 691 694
23. M.A. Goodrum, D.G.R. Siko, T. Niehues, D. Eichelbauer, and J.A. Verschoor Mycolic acids from Mycobacterium tuberculosis: purification by countercurrent distribution and T cell stimulation Microbios 106 2001 55 67
24. J. Pan, N. Fujiwara, S. Oka, R. Maekura, T. Ogura, and L. Yano Anti-cord factor (trehalose 6,6′-dimycolate) IgG antibody in tuberculosis patients recognizes mycolic acid subclasses Microbiol. Immunol. 43 1999 863 869
25. J. Gatfield, and J. Pieters Essential role for cholesterol in entry of mycobacteria into macrophages Science 288 2000 1647 1650
26. A. Brzostek, J. Pawelczyk, A. Rumijowska-Galewicz, B. Dziadek, and J. Dziadek Mycobacterium tuberculosis is able to accumulate and utilize cholesterol J. Bacteriol. 191 2009 6584 6591
27. C. De Chastellier, and L. Thilo Cholesterol depletion in Mycobacterium avium - infected macrophages overcome the block in phagosome maturation and leads to the reversible sequestration of viable mycobacteria in phagolysosome derived autophagic vacuoles Cell. Microbiol. 8 2006 242 256
28. Y. Lemmer, S.T. Thanyani, P.J. Vrey, C.H.S. Driver, L. Venter, S. van Wyngaardt, A.M.C. ten Bokum, K.I. Ozoemena, L.A. Pilcher, D.G. Fernig, A.C. Stoltz, H.S. Swai, and J.A. Verschoor Detection of antimycolic acid antibodies by liposomal biosensors Methods Enzymol. 464 2009 80 102
29. C. de Chastellier, F. Forquet, A. Gordon, and L. Thilo Mycobacterium requires an all-around closely apposing phagosome membrane to maintain the maturation block and this apposition is re-established when it rescues itself from phagolysosomes Cell. Microbiol. 11 2009 1190 1207
30. J.A. Armstrong, and P. D'arcy Hart Phagosome-lysosome interactions in cultured macrophages infected with virulent tubercle bacilli J. Exp. Med. 142 1975 1 15
31. C. Frehel, C. de Chastellier, T. Lang, and N. Rastogi Evidence for inhibition of fusion of lysosomal and prelysosomal compartments with phagosomes in macrophages infected with pathogenic Mycobacterium avium Infect. Immun. 52 1986 252 262
32. C. De Chastellier, T. Lang, and L. Thilo Phagocytic processing of the macrophage endoparasite, Mycobacterium avium, in comparison to phagosomes which contain Bacillus subtilis or latex beads Eur. J. Cell Biol. 68 1995 167 182
33. C. De Chastellier, and L. Thilo Phagosome maturation and fusion with lysosomes in relation to surface property and size of the phagocytic particle Eur. J. Cell Biol. 74 1997 49 62
34. R. Pietersen, L. Thilo, and C. de Chastellier Mycobacterium tuberculosis and Mycobacterium avium modify the composition of the phagosomal membrane in infected macrophages by selective depletion of cell surface derived glycoconjugates Eur. J. Cell Biol. 83 2004 153 158
35. D.L. Clemens, and M.A. Horwitz Characterization of the Mycobacterium tuberculosis phagosome and evidence that phagosomal maturation is inhibited J. Exp. Med. 181 1995 257 270
36. Q.N. Myrvik, E.S. Leake, and M.J. Wright Disruption of phagosomal membranes of normal alveolar macrophages by the H37Rv strain of Mycobacterium tuberculosis. A correlate of virulence Am. Rev. Respir. Dis. 129 1984 322 328
37. K.A. McDonough, Y. Kress, and B.R. Bloom Pathogenesis of tuberculosis: interaction of Mycobacterium tuberculosis with macrophages Infect. Immun. 61 1993 2763 2773
38. N. van der Wel, D. Hava, D. Houben, D. Fluitsma, M. van Zon, J. Pierson, M. Brenner, and P.J. Peters M. tuberculosis and M. leprae translocate from the phagolysosome to the cytosol in myeloid cells Cell 129 2007 1287 1298
39. B.Y. Lee, D.L. Clemens, and M.A. Horwitz The metabolic activity of Mycobacterium tuberculosis, assessed by use of a novel inducible GFP expression system, correlates with its capacity to inhibit phagosomal maturation and acidification in human macrophages Mol. Microbiol. 68 2008 1047 1060
40. J. Panyam, W. Zhou, S. Prabha, S.K. Sahoo, and V. Labhasetwar Rapid endo-lysosomal escape of poly(DL-lactide-coglycolide) nanoparticles: implications for drug and gene delivery FASEB J. 16 2002 1217 1226
41. A.J. Gomes, A.S. Faustino, A.E. Machado, M.E. Zaniquelli, T. de Paula Rigoletto, C.N. Lunardi, and L.O. Lunardi Characterization of PLGA microparticles as a drug carrier for 3-ethoxycarbonyl-2 h-benzofuro[3,2-f]-1-benzopyran-2-one. Ultrastructural study of cellular uptake and intracellular distribution Drug Deliv. 13 2006 447 454
42. F.Y. Cheng, S.P. Wang, C.H. Su, T.L. Tsai, P.C. Wu, D.B. Shieh, J.H. Chen, P.C. Hsieh, and C.S. Yeh Stabilizer-free poly(lactide-co-glycolide) nanoparticles for multimodal biomedical probes Biomaterials 29 2008 2104 2112
43. M.S. Cartiera, K.M. Johnson, V. Rajendran, M.J. Caplan, and W.M. Saltzman The uptake and intracellular fate of PLGA nanoparticles in epithelial cells Biomaterials 30 2009 2790 2798
44. C. Schliehe, C. Schliehe, M. Thiry, U.I. Tromsdorf, J. Hentschel, H. Weller, and M. Groettrup Microencapsulation of inorganic nanocrystals into PLGA microsphere vaccines enables their intracellular localization in dendritic cells by electron and fluorescence microscopy J. Control. Release 151 2011 278 285
45. R. Kalluru, F. Fenaroli, D. Westmoreland, L. Ulanova, A. Maleki, N. Roos, M. Paulsen Madsen, G. Koster, W. Egge-Jacobsen, S. Wilson, H. Roberg-Larsen, G.K. Khuller, A. Singh, B. Nyström, and G. Griffiths Poly(lactide-co-glycolide)-rifampicin nanoparticles efficiently clear Mycobacterium bovis BCG infection in macrophages and remain membrane-bound in phago-lysosomes J. Cell Sci. 126 2013 3043 3054
46. T. Onoshita, Y. Shimizu, N. Yamaya, M. Miyazaki, M. Yokoyama, N. Fujiwara, T. Nakajima, K. Makino, H. Terada, and M. Haga The behavior of PLGA microspheres containing rifampicin in alveolar macrophages Colloids Surf. B: Biointerfaces 76 2010 151 157
47. T.J. de Faria, M. Roman, N.M. de Souza, R. De Vecchi, J.V. de Assis, A.L. dos Santos, H. Bechtold, N. Winter, M.J. Soares, L.P. Silva, M.V. De Almeida, and A. Báfica An isoniazid analogue promotes Mycobacterium tuberculosis - nanoparticle interactions and enhances bacterial killing by macrophages Antimicrob. Agents Chemother. 56 2012 2259 2267
48. Y. Lemmer Assessment of Mycolic Acids as Ligand for Nanoencapsulated Anti-tuberculosis Drug Targeting 2010 Department Biochemistry, University of Pretoria 1 190
49. A. Lamprecht, N. Ubrich, M. Hombreiro Perez, C.-M. Lehr, M. Hoffman, and P. Maincent Biodegradable monodispersed nanoparticles prepared by pressure homogenization-emulsification Int. J. Pharm. 184 1999 97 105
50. M.S. Hora, R.K. Rana, J.H. Nunberg, T.R. Tice, R.M. Gilley, and M.E. Hudson Release of human serum albumin from poly(lactide-co-glycolide) microspheres Pharm. Res. 7 1990 1190 1194
51. S.P.S. Khanuja, S. Srivastava, T.R.S. Kumar, A.K. Shasany, M.P. Darokar, and S. Awasthi PCT WO 03/080860. A Quick and Sensitive Method of Quantifying Mycolic Acid W.I.P. Organisation 2003
52. S.T. Thanyani, V. Roberts, D.G. Siko, P. Vrey, and J.A. Verschoor A novel application of affinity biosensor technology to detect antibodies to mycolic acid in tuberculosis patients J. Immunol. Methods 332 2008 61 72
53. M. Beukes, Y. Lemmer, M. Deysel, J.R. Al Dulayymi, M. Baird, G. Koza, M.M. Iglesias, R.R. Rowles, C. Theunissen, J. Grooten, G. Toschi, V.V. Roberts, L. Pilcher, S. Van Wyngaardt, N. Mathebula, M. Balogun, A.C. Stoltz, and J.A. Verschoor Structure-function relationships of the antigenicity of mycolic acids in tuberculosis patients Chem. Phys. Lipids 2010 10.1016/j.chemphyslip.2010.1009.1006
54. C. De Chastellier The many niches and strategies used by pathogenic mycobacteria for survival within host macrophages Immunobiology 214 2009 526 542
55. F. Alexis, E. Pridgen, L.K. Molnar, and O.C. Farokhzad Factors affecting the clearance and biodistribution of polymeric nanoparticles Mol. Pharm. 5 2008 505 515
56. K. Ohashi, T. Kabasawa, T. Ozeki, and H. Okada One-step preparation of rifampicin/poly(lactic-co-glycolic acid) nanoparticle-containing mannitol microspheres using a four-fluid nozzle spray drier for inhalation therapy of tuberculosis J. Control. Release 135 2009 19 24
57. P.V. Kumar, A. Asthana, T. Dutta, and N.K. Jain Intracellular macrophage uptake of rifampicin loaded mannosylated dendrimers J. Drug Target. 14 2006 546 556
58. J. Cheng, B.A. Teply, I. Sherifi, J. Sung, G. Luther, F.X. Gu, E. Levy-Nissenbaum, A.F. Radovic-Moreno, R. Langer, and O.C. Farokhzad Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery Biomaterials 28 2007 869 876
59. X. Montet, R. Weissleder, and L. Josephson Imaging pancreatic cancer with a peptide-nanoparticle conjugate targeted to normal pancreas Bioconjug. Chem. 17 2006 905 911
60. F. Shamsipour, A.H. Zarnani, R. Ghods, M. Chamankhah, F. Forouzesh, S. Vafaei, A.A. Bayat, M.M. Akhondi, M. Ali Oghabian, and M. Jeddi-Tehrani Conjugation of monoclonal antibodies to super paramagnetic iron oxide nanoparticles for detection of HER2/neu antigen on breast cancer cell lines Avicenna J. Med. Biotechnol. 1 2009 27 31
61. I. Hershkovitz, H.D. Donoghue, D.E. Minnikin, G.S. Besra, O.Y.-C. Lee, A.M. Gernaey, E. Galili, V. Eshed, C.L. Greenblatt, E. Lemma, G.K. Bar-Gal, and M. Spigelman Detection and molecular characterization of 9000-year-old Mycobacterium tuberculosis from a Neolithic settlement in the Eastern Mediterranean PLoS ONE 3 2008 e3426
62. S. Zimmerli, S. Edwards, and J.D. Ernst Selective receptor blockade during phagocytosis does not alter the survival and growth of Mycobacterium tuberculosis in human macrophages Am. J. Respir. Cell Mol. Biol. 15 1996 760 770
63. F. Fenaroli, D. Westmoreland, J. Benjaminsen, T. Kolstad, F.M. Skjeldal, A.H. Meijer, M. van der Vaart, L. Ulanova, N. Roos, B. Nyström, J. Hildahl, and G. Griffiths Nanoparticles as drug delivery system against tuberculosis in zebrafish embryos: direct visualization and treatment ACS Nano 8 2014 7014 7026
64. M.A. Tracy, K.L. Ward, L. Firouzabadian, Y. Wang, N. Dong, R. Qian, and Y. Zhang Factors affecting the degradation rate of poly(lactide-co-glycolide) microspheres in vivo and in vitro Biomaterials 20 1999 1057 1062
65. S. Fredenberg, M. Wahlgren, M. Reslow, and A. Axelsson The mechanisms of drug release in poly(lactic-co-glycolic acid)-based drug delivery systems - a review Int. J. Pharm. 415 2011 34 52
66. M. Dutt, and G.K. Khuller Liposomes and PLG microparticles as sustained release antitubercular drug carriers - an in vitro-in vivo study Int. J. Antimicrob. Agents 18 2001 245 252
67. C.M. Johnson, R. Pandey, S. Sharma, G.K. Khuller, R.J. Basaraba, I.M. Orme, and A.J. Lenaerts Oral therapy using nanoparticle-encapsulated antituberculosis drugs in guinea pigs infected with Mycobacterium tuberculosis Antimicrob. Agents Chemother. 49 2003 4335 4338
68. A. Sharma, R. Pandey, S. Sharma, and G.K. Khuller Chemotherapeutic efficacy of poly (dl-lactide-co-glycolide) nanoparticle encapsulated antitubercular drugs at sub-therapeutic dose against experimental tuberculosis Int. J. Antimicrob. Agents 24 2004 599 604
69. R. Pandey, A. Zahoor, S. Sharma, and G.K. Khuller Nanoparticle encapsulated antitubercular drugs as a potential oral drug delivery system against murine tuberculosis Tuberculosis 83 2003 373 378
70. H. Ranchod Chemically Synthetic Mycolic Acids as Vaccine Adjuvants 2014 Department Biochemistry, University of Pretoria 1 83
71. A.D. Calver, A.A. Falmer, M. Murray, O.J. Strauss, E.M. Streicher, M. Hanekom, T. Liversage, M. Masibi, P.D. van Helden, R.M. Warren, and T.C. Victor Emergence of increased resistance and extensively drug-resistant tuberculosis despite treatment adherence, South Africa Emerg. Infect. Dis. 16 2010 264 271
72. P.R. Donald, and P.D. van Helden The global burden of tuberculosis - combating drug resistance in difficult times N. Engl. J. Med. 4 2009 2393 2395